Cara Therapeutics' New Pain Drug Still Has Value After Failed Clinical Trial |
| July 07, 2017 | July 2017 Bond Updates |
|
Last week, Cara Therapeutics reported that its phase 2b trial of CR845, an investigational new pain relief drug, had failed to meet its primary endpoint. Since then, the stock dropped from $26 to $15 a loss of over 40% of its value. Has the market over-reacted? |
| View more at: http://www.forbes.com/sites/kenkam/2017/07/06/cara-therapeutics-new-pain-drug-still-has-value-after-failed-clinical-trial/ |
| Related News |
|